SPARCL1: A Protein Interaction Target in Cancer and Cell Signaling

Target Name: SPARCL1

NCBI ID: G8404

SPARCL1

SPARCL1: A Protein Interaction Target in Cancer and Cell Signaling

SPARCL1 (SPARC-like protein 1 (isoform 1)) is a protein that is expressed in various tissues and cells in the human body. It is characterized by its ability to interact with other proteins, particularly SPARC-like proteins, which are a family of proteins that are known to play a role in various cellular processes.

SPARCL1 has been shown to be involved in a number of different processes in the body, including the regulation of cell signaling pathways, cell adhesion, and the development and progression of various diseases. As a result, SPARCL1 has generated a lot of interest among researchers as a potential drug target or biomarker.

One of the key reasons for the interest in SPARCL1 is its ability to interact with SPARC-like proteins. SPARC-like proteins are a family of transmembrane proteins that are characterized by their ability to interact with a specific protein called sphingomyelin. This protein is a component of cell membranes and is involved in a number of different cellular processes, including the regulation of signaling pathways and the maintenance of cell shape.

SPARCL1 has been shown to interact with SPARC-like proteins in a number of different ways. For example, studies have shown that SPARCL1 can interact with SPARC-like proteins through their extracellular domain, which consists of a region of the protein that is involved in its interactions with other proteins. This interaction between SPARCL1 and SPARC-like proteins is thought to be important for the regulation of cellular processes such as cell signaling, cell adhesion, and tissue repair.

In addition to its role in interacting with SPARC-like proteins, SPARCL1 has also been shown to be involved in the regulation of a number of different cellular processes. For example, studies have shown that SPARCL1 can be involved in the regulation of cell cycle progression. , the production of new cells, and the regulation of cell apoptosis, or programmed cell death.

SPARCL1 has also been shown to be involved in the development and progression of a number of different diseases. For example, studies have shown that SPARCL1 is involved in the development and progression of various types of cancer, including breast cancer, ovarian cancer, and colorectal cancer. This suggests that SPARCL1 may be a useful biomarker for the diagnosis and treatment of these diseases.

Despite the potential interest in SPARCL1 as a drug target or biomarker, much more research is needed to fully understand its role in the body. There are currently no approved drugs that are specifically designed to target SPARCL1, and more research is needed to determine the best way to use this protein in medical treatments.

In conclusion, SPARCL1 is a protein that is expressed in various tissues and cells in the human body. It is characterized by its ability to interact with other proteins, particularly SPARC-like proteins, which are a family of proteins that are known to play a role in various cellular processes. SPARCL1 has been shown to be involved in a number of different processes in the body, including the regulation of cell signaling pathways, cell adhesion, and the development and progression of various diseases. As a result, SPARCL1 has generated a lot of interest among researchers as a potential drug target or biomarker. Further research is needed to fully understand its role in the body and its potential as a therapeutic agent.

Protein Name: SPARC Like 1

The "SPARCL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SPARCL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets